![]() | Athina MarkouShow email addressDepartment of Psychiatry, School of Medicine, University California San Diego, 9500 Gilman Drive, M/C 0603, La Jolla, CA 92093, USA. | Department of Psychiatry, School of ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Athina Markou:Expert Impact
Concepts for whichAthina Markouhas direct influence:Nicotine withdrawal,Nicotine dependence,Brain reward function,Wistar receptors,Cocaine withdrawal,Metabotropic glutamate,Brain reward,Animal models.
Athina Markou:KOL impact
Concepts related to the work of other authors for whichfor which Athina Markou has influence:Nucleus accumbens,Animal models,Nicotine withdrawal,Drug addiction,Smoking cessation,Prefrontal cortex,Metabotropic glutamate.
KOL Resume for Athina Markou
Year | |
---|---|
2018 | Department of Psychiatry, School of Medicine, University California San Diego, 9500 Gilman Drive, M/C 0603, La Jolla, CA 92093, USA. |
2017 | Department of Psychiatry, University of California San Diego, 9500 Gilman Drive MC 0804, 92093-0804, La Jolla, CA, USA |
2016 | Department of Psychiatry, M/C 0603, School of Medicine, University of California San Diego, 9500 Gilman Drive, 92093-0603, La Jolla, CA, USA |
2015 | Department of Psychiatry, Health Sciences, University of California San Diego, La Jolla, CA, USA |
2014 | Psychiatry, University of California, San Diego, La Jolla, CA, United States |
2013 | Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, California 92093 University of California San Diego, La Jolla, California, United States of America |
2012 | Department of Psychiatry, School of Medicine, University of California San Diego, 9500 Gilman Drive, M/C 0603, 92093-0603, La Jolla, CA, USA |
2011 | Department of Psychiatry, M/C 0603, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA |
2010 | Department of Psychiatry, School of Medicine, University of California San Diego, La Jolla, California, USA |
2009 | Department of Psychiatry, School of Medicine, University of California, San Diego, 9500 Gilman Drive, 92093, La Jolla, CA, USA |
2008 | Department of Psychiatry, School of Medicine, University of California, San Diego, 9500 Gilman Drive, Mail Code 0603, 92093-0603, La Jolla, CA, USA |
2007 | Department of Psychiatry, University of California, San Diego |
2006 | Department of Molecular and Integrative Neurosciences, The Scripps Research Institute, La Jolla, California 92037, |
2005 | Molecular and Integrative Neuroscience Department, CVN-7, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA Department of Neuropharmacology, The Scripps Research Institute, 92037, La Jolla, CA |
2004 | Department of Neuropharmacology CVN-7, The Scripps Research Institute, 10550 North Torrey Pines Road, 92037, La Jolla, CA, USA |
2003 | Department of Neuropharmacology The Scripps Research Institute, La Jolla CA, USA |
Concept | World rank |
---|---|
preclinical data review | #1 |
administration bhf177 | #1 |
ly379268 counteracted | #1 |
brain sites icss | #1 |
006 base rats | #1 |
ataxia body hypothermia | #1 |
downs addiction | #1 |
antagonist mpep | #1 |
cgp56433a wistar receptors | #1 |
treatment tobacco smoking | #1 |
rats ly314582 | #1 |
animals attention rats | #1 |
9 day salt | #1 |
ameliorate prepulse | #1 |
administration cue | #1 |
glutamate reinforcement | #1 |
nondrugwithdrawing animals | #1 |
neurobiological factors relapse | #1 |
withdrawal chronic amphetamine | #1 |
wistar reinforcement gaba | #1 |
β2 nicotine | #1 |
selfadministered cocaine escalation | #1 |
cgp56433a bhf177 | #1 |
severe aie cohort | #1 |
nicotine threshold elevations | #1 |
pcpinduced disruptions | #1 |
vigorous icss | #1 |
cognitive behaviors adulthood | #1 |
cue nicotineinduced reinstatement | #1 |
erythroidine electrodes | #1 |
pams food administration | #1 |
heterocyclic male nicotine | #1 |
cgp44532 decreased | #1 |
fixed progressive | #1 |
thresholds somatic | #1 |
4day binge exposures | #1 |
0048 μg infusion | #1 |
exposure risky | #1 |
azd8418 nicotine selfadministration | #1 |
cognitive modalities | #1 |
rewardrelated constructs | #1 |
dose bupropion | #1 |
316 day base | #1 |
mpep breaking points | #1 |
nicotine selfadministration nicotine | #1 |
treatments anhedonia | #1 |
nicotine dependence humans | #1 |
individuals smoking relapse | #1 |
target medication development | #1 |
depression shared neurobiology | #1 |
Sign-in to see all concepts, it's free! | |
Prominent publications by Athina Markou
Stimulatory actions of nicotine on mesocorticolimbic dopamine transmission are partly mediated by nicotine-induced glutamate release acting on ionotropic and metabotropic glutamate (mGlu) receptors. Because both presynaptic inhibitory mGlu2/3 and postsynaptic excitatory mGlu5 receptors provide potential targets for treatment of aspects of nicotine dependence, we examined interacting effects of mGlu5 (2-methyl-6-(phenylethynyl)-pyridine, MPEP) and mGlu2/3 (LY341495) receptor antagonists ...
Known for Nicotine Withdrawal | Mglu5 Receptor | Reward Deficits | Administration Mpep | Glutamate Transmission |
The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat
[ PUBLICATION ]
RationalePrevious work has indicated a potential role for γ-aminobutyric acid-B (GABAB) receptor agonists in treating drug addiction in humans. Specifically, GABAB receptor agonists decreased cocaine, heroin and nicotine self-administration in rats.ObjectivesThe purpose of the present studies was to extend previous findings by assessing the effects of additional GABAB receptor agonists on nicotine self-administration and food-maintained responding, under both fixed and progressive ratio ...
Known for Gabab Receptor Agonists | Decreased Nicotine | Progressive Ratio Schedule | Administration Rats | Fixed Ratio |
Acute administration of gamma-aminobutyric acid (GABA)-B receptor agonists decreases nicotine, cocaine, ethanol, and heroin self-administration and also decreases food-maintained responding and suppresses locomotor activity at high doses. GABA(B) receptor-positive modulators may represent potentially improved therapeutic compounds because of their fewer side effects than receptor agonists. The present study investigated the effects of administration of the GABA(B) receptor-positive ...
Known for Brain Reward Function | Gabab Receptors | Positive Modulation | Decreased Nicotine | Effects Bhf177 |
Previous studies suggested that metabotropic glutamate 5 (mGlu5) receptors play an important role in the reinforcing effects of abused drugs. The present experiments evaluated the effects of the mGlu5 receptor antagonist, MPEP (2-methyl-6-(phenylethynyl)-pyridine hydrochloride; 1-10 mg/kg, salt, i.p.), in rat models of nicotine-seeking behavior that may have relevance to relapse to drug-taking. Male Wistar rats (with restricted access to food) were trained to nose-poke to receive ...
Known for Induced Reinstatement | Metabotropic Glutamate | Animal Conditioning | Wistar Receptor | Administration Behavior |
RationaleThe aversive aspects of nicotine withdrawal contribute to high relapse rates to tobacco smoking after cessation attempts.ObjectivesTo investigate the influence of nicotine dose, duration of nicotine exposure, and withdrawal history on the severity of nicotine withdrawal in rats, as assessed by brain stimulation reward thresholds and somatic signs of withdrawal.MethodsRepeated spontaneous and precipitated withdrawals were investigated through four successive removals of osmotic ...
Known for Nicotine Exposure | Somatic Signs | Threshold Elevations | Dose Duration | Withdrawal Rats |
RationaleNicotine increases glutamate release in the ventral tegmental area and the nucleus accumbens, and thus enhances dopamine neurotransmission in the mesolimbic system that has been implicated in mediating the rewarding effects of drugs. Metabotropic glutamate receptors 5 (mGluR5) are found in the nucleus accumbens and may play a role in modulating the post-synaptic response to both glutamate and dopamine.ObjectivesThe present study investigated the effects of the mGluR5 antagonist ...
Known for Mglur5 Antagonist | Rats Mice | Wistar Receptor | Nicotine Administration | Mpep Decreased |
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat
[ PUBLICATION ]
RationaleBupropion is an atypical antidepressant and the only non-nicotine-based therapy approved for smoking cessation. Its use has raised much debate as to how a non-nicotine-based agent can aid in smoking cessation.ObjectivesWe assessed the effects of bupropion on brain reward function under baseline conditions and subsequent to withdrawal from chronic nicotine administration in rats.MethodsA discrete-trial intracranial self-stimulation paradigm procedure was used that provides one ...
Known for Brain Reward Function | Nicotine Withdrawal | Somatic Signs | Wistar Receptors | Bupropion Rats |
This study investigated the role of ionotropic and metabotropic glutamate receptors in the deficits in brain reward function, as measured by elevations in intracranial self-stimulation (ICSS) reward thresholds, associated with nicotine withdrawal. The group II metabotropic glutamate (mGluII) receptor agonist LY314582 [a racemic mixture of LY354740 ([+]-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid])] (2.5-7.5 mg/kg) precipitated withdrawal-like elevations in ICSS thresholds, a ...
Known for Glutamate Receptors | Nicotine Withdrawal | Reward Deficits | Isoxazole Propionate | Icss Thresholds |
Nicotine is considered an important component of tobacco responsible for the smoking habit in humans. Nicotine increases glutamate-mediated transmission throughout brain reward circuitries. This action of nicotine could potentially contribute to its intrinsic rewarding and reward-enhancing properties, which motivate consumption of the drug. Here we show that the competitive N-methyl-D-aspartate (NMDA) receptor antagonist LY235959 (0.5–2.5 mg per kg) abolished nicotine-enhanced brain ...
Known for Nmda Receptors | Ventral Tegmental Area | Brain Reward | Effects Nicotine | Central Nucleus |
Acute administration of γ-aminobutyric acid B (GABAB) receptor agonists decreased nicotine, cocaine, ethanol, and heroin self-administration. GABAB receptor agonists also decreased cue-induced cocaine craving or seeking in humans and animals, respectively. The present study investigated the effects of repeated subcutaneous administration of the GABAB receptor agonist CGP44532 on nicotine- and food-maintained responding under a fixed ratio 5 schedule of reinforcement. The second part of ...
Known for Repeated Administration | Gabab Receptor | Cueinduced Reinstatement | Decreased Cue | Nicotine Seeking |
The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats
[ PUBLICATION ]
RationaleThe metabotropic glutamate (mGlu5) receptor subtype 5 antagonist MPEP attenuates self-administration of numerous drugs of abuse.ObjectivesThe purpose of the present study was to explore whether MPEP-induced decreases in nicotine and cocaine self-administration reflect attenuation of the reinforcing and incentive motivational effects of nicotine and cocaine. The effects of MPEP on breaking points maintained by nicotine, cocaine or food were assessed using a progressive ratio ...
Known for Nicotine Cocaine | Glutamate Receptor | 5 Antagonist | Effects Mpep | Test Session |
The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity
[ PUBLICATION ]
Phencyclidine (PCP), a non-competitive antagonist of ionotropic N-methyl-D-aspartate (NMDA) receptors, produces psychotomimetic effects, such as a disruption in prepulse inhibition (PPI) of the startle response. NMDA antagonists also induce locomotor hyperactivity in rodents. We hypothesized that, like NMDA receptors, metabotropic glutamate receptors (mGluRs) modulate PPI and locomotor activity either alone or, in the case of mGluR5, via interaction with NMDA receptors. Rats treated with ...
Known for Locomotor Activity | Mglur5 Antagonist | Prepulse Inhibition | Nmda Receptors | Dawley Receptor |
In these experiments we sought to establish the intravenous (IV) self-administration of cocaine under a second-order schedule of reinforcement in order: (i) to obtain reliable, drug-free levels of responding with cocaine as a reinforcer, and (ii) to enable investigation of the neural mechanisms by which arbitrary cues gain motivational salience and, as conditioned reinforcers, control over drug-seeking behaviour. Initially, each infusion of cocaine was made contingent upon a response on ...
Known for Basolateral Amygdala | Order Schedule | Excitotoxic Lesions | Seeking Behaviour | Cocaine Infusion |
RATIONALE: γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain and is implicated in the modulation of central reward processes. Acute or chronic administration of GABA(B) receptor agonists or positive modulators decreased self-administration of various drugs of abuse. Furthermore, GABA(B) receptor agonists inhibited cue-induced reinstatement of nicotine- and cocaine-seeking behavior. Because of their fewer adverse side effects compared with GABA(B) receptor ...
Known for Gabab Receptor | Nicotine Seeking | Induced Reinstatement | Addictive Behavior | Administration Decreased |